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ABSTRACT 
 
Objective 
Cochrane Acute Respiratory Infections (ARI) Group conducts systematic reviews of the evidence for 
treatment and prevention of ARIs. We report the results of a prioritisation project, aiming to identify 
highest priority systematic review topics. 
 
Study design/setting 
The project consisted of 2 Phases. Phase 1 analysed the gap between existing RCTs and Cochrane 
Systematic Reviews (reported previously). Phase 2 (reported here) consisted of a two-round survey. 
In round 1, respondents prioritised 68 topics and suggested up to 10 additional topics; in Round 2, 
respondents prioritised top 25 topics from Round 1. 
 
Results 
Respondents included clinicians, researchers, systematic reviewers, allied health, patients, and 
carers, from 33 different countries. In Round 1, 154 respondents identified 20 priority topics, most 
commonly selecting topics in non-specific ARIs, influenza, and common cold. 50 respondents also 
collectively suggested 134 additional topics. In Round 2, 78 respondents prioritised top 25 topics, 
most commonly in the areas of non-specific ARIs, pneumonia and influenza.   
 
Conclusion 
We generated a list of priority systematic review topics, to guide the Cochrane ARI Group’s 
systematic review work for the next 24 months. Stakeholder involvement enhanced the 
transparency of the process, and will increase the usability and relevance of the Group’s work to 
stakeholders.  
 
 
 
 
KEYWORDS:  
Acute respiratory infections, prioritisation, systematic reviews, stakeholders, Cochrane 
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HIGHLIGHTS 
 
Key findings 
• We analysed Cochrane Acute Respiratory Infections Group’s register of randomised 
controlled trials, and identified 68 systematic review topics which had adequate volume of 
RCT evidence to systematically review but no corresponding Cochrane Review  
• We prioritised 21 of those 68 topics in a two-round online survey involving a broad range of 
stakeholders  
 
What this adds to what is known?  
• We present a new approach to prioritisation of Cochrane systematic review topics, which 
involves combining of the evidence/systematic review gap analysis, with stakeholder 
engagement  
 
What is the implication and what should change now?  
• The prioritisation project will help to enhance the transparency of systematic review topic 
selection in the next 24 months,  
• The involvement of stakeholders in the prioritisation project will help to increase the 
relevance of Cochrane Acute Respiratory Infections Group’s work to a wide range of 
stakeholders  
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1. INTRODUCTION 
 
Cochrane is a global initiative, which produces systematic reviews in 53 healthcare subject-focused 
Cochrane Review Groups (CRGs). Each CRG prepares systematic reviews in teams of healthcare 
professionals – together with researchers, consumers and patients – on a volunteer basis. Oversight 
is provided by editorial teams. The Cochrane Acute Respiratory Infections (ARI) CRG focuses on 
diseases such as the common cold, sore throat, tonsillitis, sinusitis, influenza, and acute otitis media, 
but also acute respiratory infections in patients in hospital, and in intensive care. It produces about 
10 Cochrane systematic reviews and 8 updates each year. 
 
CRGs function more actively than traditional editorial groups, by providing editorial support at every 
stage of the systematic review process and providing feedback to ensure that reviews are of the 
highest quality, while traditional journals usually have a greater focus on accepting or rejecting 
articles. Accordingly, not all systematic reviews proposed by author teams or requested externally, 
can be undertaken by CRGs due to limited resources. Deciding whether to accept or reject a review 
proposal can be straightforward – for example, the proposed author team has insufficient expertise 
to conduct a Cochrane review, or the proposed topic has already been covered in a Cochrane 
review. However, in some instances, it is necessary to support decisions to accept or reject proposals 
or commissions for Cochrane reviews. Many CRGs have therefore undertaken prioritisation 
exercises, using a variety of methods[1], including: online surveys; Delphi panels; workshops; 
evidence mapping; stakeholder partnerships; consultations with partner organisations, experts and 
other stakeholders; scoping exercises; searches of trial registries; horizon scanning; interviews with 
policy- and decision-makers; and combinations of these.[2-10]  
 
We report here the results of Cochrane Acute Respiratory Infections Group’s prioritisation project, 
which consisted of two phases. Phase 1 was an analysis of the gap between existing RCT evidence 
and existing Cochrane Systematic Reviews [11]. Phase 2 consisted of a two-round survey to identify 
top 20 priority topics in the area of acute respiratory infections. The aim of the project was to 
identify the 20 highest priority systematic review topics in the area of acute respiratory infections, to 
guide the Group’s work for the next two years. 
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2. MATERIAL AND METHODS  
This project consisted of 2 phases. 
2.1. Phase 1 
In phase 1, we analysed the ARI CRG’s register of randomised controlled trials (RCTs), and compared 
this against the ARI CRG’s systematic review topics list. The aim of this phase was to identify those 
systematic review topics (health condition and intervention) for which RCTs exist, but no 
corresponding Cochrane Review has been conducted. To achieve this, we analysed 157 Cochrane ARI 
Reviews and 5,393 ARI-specific RCTs from the Cochrane ARI trials register, and found that a 
substantial number (2174 or 41%) of RCTs had not been systematically reviewed. The number of 
systematic review topics with no Cochrane Review and an available RCT was 649 out of a total of 764 
(85%). Phase 1 is completed and its results have been previously reported[11]  
2.2. Phase 2  
We report here on the results of Phase 2 of the prioritisation project. Of the 649 systematic review 
topics which lacked a Cochrane Review but had existing RCT evidence (identified in Phase 1), we 
excluded those topics for which the RCT evidence was limited (4 RCTs or fewer). This left 68 
systematic review topics for inclusion in Phase 2. The aim of Phase 2 was to prioritise those topics, to 
identify top 20 priority systematic reviews. Phase 2 consisted of a two-round survey, implemented 
using the surveymonkey.com platform. Ethics approval for this project was obtained from the Bond 
University Ethics Committee, approval number 16129 (11 Sept 2017). 
 
2.2.1 Phase 2 Round 1 
Round 1 survey consisted of 5 questions: 3 demographic questions and 2 questions pertaining to 
topic prioritisation (see Appendix A).  
 
Questions 1-3 queried the respondents’ professional identification (one of 13 possibilities including 
‘other’), country of residence, and email address to enable contact for Round 2, respectively. 
Question 4 listed all of the systematic review topics that were identified in Phase 1, and for which 5 
or more RCTs existed, but which lacked a Cochrane Systematic Review (n=68). Each topic provided 
the following information: health condition, intervention, and the number of existing RCTs. The 
respondents were asked to tick up to 20 topics they thought should be prioritised for systematic 
review by the Cochrane ARI Group. Question 5 allowed respondents to suggest up to 10 additional 
topics that respondents thought should also be prioritised for systematic review.  
 
6 
 
The survey opened on 27 October 2017 and closed on 24 November 2017. The link to the survey was 
disseminated to the Cochrane ARI Group’s mailing list of systematic review authors and consumers, 
Cochrane Comms Network Digest and Cochrane Survey Round-Up page, the Cochrane Consumer 
Network, and Evidence-Based Healthcare (EBHC) mailing list. To ensure broad response from 
consumers and patients, we also contacted several consumer health groups in Australia (Health 
Consumers’ Alliance of South Australia and Health Consumers Queensland disseminated survey link 
to their members), and disseminated the request and survey link to members of the Patient and 
Consumer Interest Group of Health Technology Assessment international (HTAi) for assistance with 
further dissemination of the survey to their own networks of patient groups.  
 
The results of Round 1 were analysed to identify the top 25 systematic review topics – those that 
received the highest number of identifications as “priority” by respondents in Question 4. The 
systematic review topics nominated by respondents in Question 5 were checked against the 
Cochrane Library to identify whether a systematic review on that topic currently exists. Where a 
systematic review topic did not exist, and was suggested with sufficiently high frequency to match 
that from the top 25 topics, it was advanced to Round 2.  
 
2.2.2 Phase 2 Round 2  
The Round 2 survey consisted of a single question, asking respondents to choose up to 10 topics 
they felt should be prioritised, from a list of top 25 topics that were identified in Round 1. We 
contacted only those participants who provided their email in Round 1. Round 2 opened on 13 
December 2017, and closed 8 January 2018. One reminder email was sent on 20 December 2017. 
The responses were analysed to identify top 20 systematic review topics – i.e. those 20 topics that 
received the highest number of identifications as a “priority” by all participants.  
3. RESULTS  
3.1 Round 1  
In Round 1, we received 154 responses; 6 minutes was typically spent by each participant to 
complete the survey.  
3.1.1 Question 1: Which of these best describes you?  
Respondents were asked to tick all the categories which applied to them or had applied to them 
within the past 12 months. Respondents who were not captured by the provided categories were 
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able to tick the ‘other’ box and free-type a response. Because respondents were able to tick more 
than one box, the responses do not add up to 100%.    
 
One hundred and fifty four respondents answered this question, with the top responses being 
physician (41%), researcher (37%), and systematic reviewer (29%) (Table 1). Twenty three individuals 
self-identified as ‘other’, with the highest number of those responses including members of other 
professional groups (e.g. teacher, librarian, etc.) (n=6) and students (n=5). No respondents self-
identified as research funders.  
 
Table 1: Professional affiliation of the respondents 
Professional affiliation Responses n(%) 
Physician 63 (41) 
Researcher 57 (37) 
Systematic reviewer (Cochrane or non-Cochrane) 44 (29) 
Other (please type into a box below) 23 (15) 
Patient with an acute respiratory infection 22 (14) 
Member of a patient organisation (e.g. patient advocacy group, disease-specific 
organisation, etc.) 
20 (13) 
Carer of a patient with an acute respiratory infection 16 (10) 
Guideline developer 13 (8) 
Allied health (e.g. pharmacist, dietician, physiotherapist, etc.) 11 (7) 
Health policy-maker 8 (5) 
Decision-maker 3 (2) 
Nurse 1 (1) 
Research funder 0 (0) 
 
3.1.2 Question 2: Where do you presently live?   
One hundred and fifty four respondents answered this question. Respondents were broadly 
distributed geographically, representing 33 countries. The highest numbers of responses were 
obtained from European (n=63), North American (n=36) and Asian (n=25) countries, driven primarily 
by a large number of responses from the United Kingdom (n=24), Canada (n=21) and India (n=9), 
respectively. Sizeable number of responses were also obtained from Australia and Oceania (n=18). 
Fewer than 10 responses were obtained from countries in Africa (n=4) and South America (n=5) 
(Table 2). 
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Table 2: Location of the respondents 
Country Number of 
respondents 
United Kingdom 24 
Canada 21 
Australia 16 
United States 14 
India  9 
Spain  8 
The Netherlands 8 
Italy 5 
Belgium 4 
Brazil 4 
France 4 
China 3 
Denmark 3 
Germany 3 
Japan 3 
Unclear or unstated 3 
New Zealand 2 
Nigeria 2 
Switzerland 2 
Other countries (1 respondent each): Algeria, Colombia, Indonesia, Iran, Ireland, Israel, 
Malaysia, Mexico, Nepal, Philippines, South Africa, Sri Lanka, Sweden, Syria, Taiwan, 
Thailand 
16 
 
3.1.3 Question 3: Please provide your email address   
So that we could contact the respondents in round 2, we requested their email addresses. One 
hundred and forty six usable addresses were provided; non-usable responses included: “gmail” 
“a@a” “a”, etc.  
 
3.1.4 Question 4: Identify up to top 20 priority systematic review topics  
Respondents were provided with a list of 68 potential systematic review topics. Each topic consisted 
of the following information: health condition, intervention, and the volume of existing RCT 
evidence. In order to pre-empt the guiding of responses by the volume of RCT evidence, the topics 
were listed alphabetically by health condition. Respondents were asked to tick up to 20 topics they 
thought should be prioritised.  
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One hundred and thirty three individuals answered this question – i.e. 21 of the respondents who 
completed questions 1-3 did not answer the question. The 20 topics that garnered the highest 
number of responses are presented in Table 3, below; the full list of 68 topics as prioritised by 
respondents is presented in Appendix B. 
Each of the top 20 priority topics was selected by 25% or more respondents. “Acute respiratory 
infection non-specific” was the most frequently selected category – 7 of the topics selected as top 20 
in Round 1 pertain to this. Influenza topics were the next most common (5 in the top 20), and 
common cold was third most commonly selected health condition (3 in the top 20). The 
interventions selected by the greatest number of respondents were: vitamins and supplements 
(including specific type of vitamin) (n=4); Nonsteroidal anti-inflammatory drugs (NSAIDs) (n=3); 
vaccination (n=3) (vaccination was also included in top 20 once as a ‘health condition’ – vaccination 
adverse events).   
3.1.5 Question 5: Suggest up to ten further systematic review topics not listed in Question 
4 
Respondents were asked to suggest up to 10 additional systematic review topics which were not 
listed in Question 4, but they thought should be prioritised. Of 154 respondents, 50 suggested at 
least one topic, and 34 suggested 2 topics – 2 respondents suggested 10 topics.  
 
A total of 134 individual topics were suggested. Of those, 50 suggested topics could not be searched 
for existing systematic reviews in the Cochrane Library due to: insufficient information about health 
condition (e.g. too general a statement, such as “all” or “respiratory illnesses”); insufficient 
information about intervention (e.g. “treatment,” “anything,” or left unstated); falling outside the 
remit of the Cochrane ARI Group (e.g. smoking interventions, transplantation).  
 
Eighty four topic suggestions were sufficiently detailed to search for existing systematic reviews in 
the Cochrane Library. The highest number of disease areas included: pneumonia (n=14), common 
cold (n=10), influenza (n=9) and pharyngitis/sore throat (n=8). The most commonly suggested 
interventions included: honey (n=8), steroids or corticosteroids (n=8), and antimicrobials or antivirals 
(n=7).  The full list of searchable topics is provided in Appendix C, together with titles of existing 
Cochrane Systematic Reviews where available. 
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3.2 Round 2  
In Round 2, respondents were presented with a list of top 25 topics identified in Round 1, and asked 
to tick up to 10 topics they think should be prioritised for Cochrane ARI Group systematic reviews; 
The survey was disseminated to 146 respondents who provided usable email addresses in round 1, 
and received 78 responses (53% participation rate).  
 
We list the top 21 topics identified in Round 2 of the survey (Table 3); the full list is presented in 
Appendix D. Twenty one, rather than 20 topics are presented, as each of these topics was selected 
by at least 27% of the respondents; the 22nd topic was prioritised by 24% of respondents, thus top 
21 formed a natural break point.  
 
“Acute respiratory infection – non-specific” was the most commonly selected disease category – 6 
topics selected; this was followed by pneumonia (n=3) and influenza (n=3). Amongst the top 21 
priority topics, the most common interventions of interest were: antivirals (n=3), vaccination as 
intervention (n=3) (NB: also once chosen as ‘health condition’); complementary and alternative 
medicine (CAM) (n=2); vitamins specific or general (n=2); NSAIDs (n=2).   
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Table 3: Systematic review topics prioritised by respondents in Round 1 and Round 2 of the survey 
   Round 1  Round 2 
Systematic Review Topic RCTs*  Responses 
n (%)  
Rank 
order  
 Responses 
n (%)  
Rank 
order  
ARI nonspecific – Vaccination 18  36 (26) 14 =  40 (51) 1 
ARI nonspecific – Antiviral 10  34 (26) 14 =  36 (46) 2 
ARI nonspecific – NSAIDs 36  50 (38) 1 =  34 (44) 3= 
ARI nonspecific - Vitamins and 
supplements 
19  42 (32) 6  34 (44) 3= 
Influenza - Infection control 5  50 (38) 1 =  32 (41) 5= 
Otitis media - Antitussive / 
decongestant / expectorant / mucolytic 
23  -- --  32 (41) 5= 
Pharyngitis / sore throat – NSAIDs 31  -- --  32 (41) 5= 
Sinusitis - CAM  10  36 (27) 10 =  30 (38) 8 
ARI nonspecific – Corticosteroid 8  48 (36) 4  28 (36) 9 
Bronchiolitis - CAM  17  38 (29) 8 =  27 (35) 10 
ARI nonspecific - Vitamin C 11  49 (37) 3  26 (33) 11= 
Influenza - Diagnostic test 5  36 (27) 10 =  26 (33) 11= 
Pneumonia - Delivery of healthcare 12  -- --  26 (33) 11= 
Common cold – Antiviral 27  -- --  25 (32) 14= 
Pneumonia – Antiviral 5  -- --  25 (32) 14= 
Common cold - Nasal lavage 5  35 (26) 14 =  25 (29) 16= 
Pneumonia - Humidification/steam 16  -- --  23 (29) 16= 
Vaccination adverse effects – 
Anaesthetic 
5  33 (25) 18 =  23 (29) 18 
Streptococcus / "strep" – Vaccination 5  38 (29) 8 =  22 (28) 19 
Bronchiolitis - Saline 12  -- --  21 (27) 20= 
Influenza – vaccination reminder 17  40 (30) 7  21 (27) 20= 
Common cold – Vitamins and 
supplements 
5  45 (34) 5  -- -- 
Pharyngitis/sore throat – NSAIDs 31  36 (27) 10 =  -- -- 
Influenza - Vitamins and supplements 5  34 (26) 14 =  -- -- 
ARI nonspecific – Paracetamol 9  33 (25) 18 =  -- -- 
Influenza - NSAIDs 5  33 (25) 18 =  -- -- 
*The number of RCTs in CENTRAL for which no corresponding Cochrane review has been conducted.  
Abbreviations: NSAIDs – nonsteroidal anti-inflammatory drugs; CAM – complementary and alternative medicine; ARI – 
acute respiratory infection 
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4. DISCUSSION 
 
We report here on the results of a priority-setting project undertaken by the Cochrane ARI Group. 
These priorities, together with the other priority setting exercises completed and underway, should 
enable a more objective approach to accepting or rejecting, and also for commissioning, Cochrane 
reviews for the ARI CRG.  
 
The prioritisation exercise yielded 21 high priority systematic review topics in the area of acute 
respiratory infections. There was a surprising change in topic priorities between the two survey 
rounds – only 1 topic, NSAIDs for non-specific ARIs, remained in the top 3 after the second round. 
Two topics that were not included among the priorities in Round 1, were included as top 5 priorities 
in Round 2: antitussive/decongestant/expectorant/mucolytic for otitis media, and NSAIDs for 
pharyngitis. Reasons for the lack of consistency between rounds may include: different respondents 
nominating different priorities; problems with classification (the same term might be used 
differently by respondents – for example, some respondents may have nominated ARI non-specific 
interchangeably with Common cold); some terms may have been confusing to respondents (e.g. 
sinusitis is known to be a confusing clinical term covering many conditions); and simple whimsy 
(which might suggest that the different preferences change readily in those with weakly held 
choices). 
 
The rank order of topics was unrelated to the amount of evidence (the number of RCTs in CENTRAL 
available for that topic). The highest volume of evidence (36 RCTs) was for NSAIDs for nonspecific 
ARI, which ranked 3rd in Round 2. However, we might not expect this, as we were asking what 
questions should be asked, rather than what questions had been asked (which might be influenced 
by commercial interests, and many other factors other than what the community wants answers to).  
 
The approach we adopted to identifying the priorities has several limitations. First, the respondents 
were drawn from a large pool, including Cochrane authors, consumers, healthcare professionals, and 
others. Although the respondents are therefore likely to represent many differing viewpoints, the 
responses may suffer from response bias, and represent the viewpoints of those with a strong prior 
belief. Second, to ensure a large participation by consumers and patients, we targeted dissemination 
of the survey to Cochrane Consumer Network, and patient and consumer groups. However, the 
participation of individuals who self-identified as patients, members of patient organisations, and 
carers was low - 14%, 13% and 10%, respectively. However, because ARIs represent a group of 
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diseases which everyone experiences, it may be reasonable to assume that participants might 
respond as patients as well as researchers, clinicians and systematic reviewers. Finally, it is not 
possible to estimate the response rate in Round 1. However, this is not uncommon in multi-round 
prioritisation projects.[7, 12] Nevertheless, the 53% response rate in round 2, is 10% lower than 
response rates in similar two-round survey prioritisation exercises conducted by other Cochrane 
groups[5, 7] and may have exaggerated the biases noted above.  
 
This prioritisation project also has some methodological strengths. First, we sought participants from 
a wide range of professional backgrounds, interests and viewpoints. Second, we implemented both 
rounds of the survey online, in order to control for show-of-hand bias, and feelings of intimidation or 
suggestibility that patients and consumers may feel in an open discussion such as a face-to-face 
workshop or focus group.[13] Finally, our approach to prioritisation was deliberately structured to 
include both pre-specified topics and an option for respondents to suggest additional topics. 
Prioritisation projects relying solely on respondents to write-in their proposed topics have been 
conducted,[7] or are currently in progress,[14] however, this approach has previously been found to 
yield a very large number of unanswerable questions. For example, a similar exercise by the 
Cochrane Tobacco Addiction Group found that of the 258 questions suggested by the respondents, 
183 (or 71%) were unanswerable.[7] Nevertheless, a wide variety of approaches for prioritising 
systematic review topics have been successful both within Cochrane and in other contexts, and no 
single approach is preferred.[15, 16] 
5. CONCLUSION 
This prioritisation exercise has successfully generated a list of priority systematic review topic to 
guide the systematic review work in the area of acute respiratory infections. The involvement of a 
wide range of stakeholders in the exercise will help to enhance the transparency of topic selection in 
the next 24 months, and increase the relevance of the Group’s work to various stakeholders. Next, 
the Group is planning an analysis of the TRIP database, to estimate the frequency and types of 
questions that clinicians ask in the area of acute respiratory infections. Together with the present 
results, this should yield a fuller picture of the key issues and priorities in the area of acute 
respiratory infections.   
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APPENDIX A – Survey Round 1   
 
Cochrane Acute Respiratory Infections Group 
Systematic Review Priority Setting Project  
 
 
ABOUT YOU 
 
1. Which of these best describes you? (Please tick ALL that apply/have applied to you within 
the last 12 months) 
 
  Physician 
  Nurse 
  Allied health (e.g. pharmacist, dietician, physiotherapist, etc.)  
  Health policy-maker 
  Decision-maker  
  Research funder  
  Guideline developer  
  Systematic reviewer (Cochrane or non-Cochrane)  
  Patient with acute respiratory infection  
  Carer of a patient with an acute respiratory infection   
  Member of a patient organisation (e.g. patient advocacy organisation, disease-specific 
organisation, etc.)  
  Researcher 
  Other (please type in below)  
 
 
2. In what country do you currently live? (Please type in below)  
 
 
3. So that we may contact you for the second round, please type in your email address 
below. (If you wish to remain anonymous, please use a generic email address – e.g. Gmail, 
Hotmail, etc. – rather than your workplace email).  
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4. Please tick up to 20 topics that you think should be prioritised for a systematic review. 
The topics (health condition, intervention, existing volume of randomised controlled trial 
evidence i.e. RCTs) are listed below, alphabetically, by health condition.  
 
Tick 
box 
Health condition - Intervention - Volume of existing evidence (RCTs) 
  Adenovirus - Vaccination - existing evidence: 6 Randomised Controlled Trials (RCTs) 
  Acute respiratory infection: nonspecific - Nonsteroidal anti - inflammatory drugs (NSAIDs) - 
existing evidence: 36 RCTs 
  Acute respiratory infection: nonspecific - Vitamin A - existing evidence: 23 RCTs 
  Acute respiratory infection: nonspecific - Vitamins and supplements - existing evidence: 19 RCTs 
  Acute respiratory infection: nonspecific - Vaccination - existing evidence: 18 RCTs 
  Acute respiratory infection: nonspecific - Vitamin C - existing evidence: 11 RCTs 
  Acute respiratory infection: nonspecific - Antiviral - existing evidence: 10 RCTs 
  Acute respiratory infection: nonspecific - Paracetamol - existing evidence: 9 RCTs 
  Acute respiratory infection: nonspecific - Zinc - existing evidence: 9 RCTs 
  Acute respiratory infection: nonspecific - Corticosteroid - existing evidence: 8 RCTs 
  Acute respiratory infection: nonspecific - Analgesic / antipyretic - existing evidence: 7 RCTs 
  Acute respiratory infection: nonspecific - Immunoglobulin - existing evidence: 7 RCTs 
  Acute respiratory infection: nonspecific - Antiseptic - existing evidence: 5 RCTs 
  Acute respiratory infection: nonspecific - Mast cell stabiliser - existing evidence: 5 RCTs 
  Bronchiolitis - Complementary and alternative medicine (CAM) - existing evidence: 17 RCTs 
  Bronchiolitis - Saline – existing evidence: 12 RCTs 
  Bronchiolitis - Antitussive / decongestant / expectorant / mucolytic – existing evidence: 6 RCTs 
  Bronchiolitis - Vaccination – existing evidence: 6 RCTs 
  Bronchiolitis - Antiviral - existing evidence: 5 RCTs 
  Bronchiolitis - Immunotherapy - existing evidence: 5 RCTs 
  Bronchitis, acute - Zinc - existing evidence: 7 RCTs 
  Common cold - Immunotherapy - existing evidence: 34 RCTs 
  Common cold - Antiviral - existing evidence: 27 RCTs 
  Common cold - Analgesic / antipyretic - existing evidence: 7 RCTs 
  Common cold - Flavinoid - existing evidence: 5 RCTs 
  Common cold - Nasal lavage - existing evidence: 5 RCTs 
  Common cold - Vitamins and supplements - existing evidence: 5 RCTs 
  Infectious mononucleosis - Antiviral - existing evidence: 10 RCTs 
  Influenza - Vaccination reminder – existing evidence: 17 RCTs 
  Influenza - Immunotherapy – existing evidence: 13 RCTs 
  Influenza - Diagnostic test – existing evidence: 5 RCTs 
  Influenza - Infection control – existing evidence: 5 RCTs 
  Influenza - Nonsteroidal anti - inflammatory drugs (NSAIDs) – existing evidence: 5 RCTs 
  Influenza - Vitamins and supplements – existing evidence: 5 RCTs 
  Meningitis - Antifungal – existing evidence: 7 RCTs 
  Otitis media - Antitussive / decongestant / expectorant / mucolytic – existing evidence: 23 RCTs 
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  Otitis media - Antihistamine – existing evidence: 13 RCTs 
  Otitis media - Complementary and alternative medicine (CAM) – existing evidence: 10 RCTs 
  Otitis media - Corticosteroid – existing evidence: 9 RCTs 
  Otitis media - Nonsteroidal anti - inflammatory drugs (NSAIDs) – existing evidence: 7 RCTs 
  Otitis media - Delivery of health care – existing evidence: 6 RCTs 
  Otitis media - Surgery – existing evidence: 5 RCTs 
  Pharyngitis / sore throat - Nonsteroidal anti - inflammatory drugs (NSAIDs) - existing evidence: 31 
RCTs 
  Pharyngitis / sore throat - Antiseptic - existing evidence: 7 RCTs 
  Pharyngitis / sore throat - Paracetamol - existing evidence: 6 RCTs 
  Pharyngitis / sore throat - Analgesic / antipyretic - existing evidence: 5 RCTs 
  Pharyngitis / sore throat - Immunotherapy - existing evidence: 5 RCTs 
  Pharyngitis / sore throat - Vaccination - existing evidence: 5 RCTs 
  Pneumonia - Humidification / steam - existing evidence: 16 RCTs 
  Pneumonia - Delivery of health care - existing evidence: 12 RCTs 
  Pneumonia - Suction - existing evidence: 11 RCTs 
  Pneumonia - Complementary and alternative medicine (CAM) - existing evidence: 9 RCTs 
  Pneumonia - H2 Antagonist (i.e. H2 blockers) - existing evidence: 9 RCTs 
  Pneumonia - Antiseptic - existing evidence: 8 RCTs 
  Pneumonia - Immunoglobulin - existing evidence: 7 RCTs 
  Pneumonia - Oral care - existing evidence: 7 RCTs 
  Pneumonia - Ventilation - existing evidence: 7 RCTs 
  Pneumonia - Enteral nutrition - existing evidence: 6 RCTs 
  Pneumonia - Granulocyte - colony stimulating factor (G - CSF) - existing evidence: 6 RCTs 
  Pneumonia - Antiviral - existing evidence: 5 RCTs 
  Pneumonia - Sucralfate - existing evidence: 5 RCTs 
  Respiratory syncytial virus - Antiviral - existing evidence: 16 RCTs 
  Respiratory syncytial virus - Vaccination - existing evidence: 15 RCTs 
  Respiratory syncytial virus - Corticosteroid - existing evidence: 12 RCTs 
  Respiratory syncytial virus - Immunotherapy - existing evidence: 5 RCTs 
  Streptococcus / "strep" - Vaccination - existing evidence: 5 RCTs 
  Sinusitis - Complementary and alternative medicine (CAM) - existing evidence: 10 RCTs 
  Vaccination adverse effects - Anaesthetic - existing evidence: 5 RCTs 
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5. OPTIONAL: Please suggest up to 10 systematic review topics (acute respiratory condition 
and therapy) that are NOT listed in the table above, but you think should also be 
systematically reviewed, and state why this topic is important. For example: Garlic for the 
common cold, because it is believed that it works and would be good to see if it's true.  
  
Topic 1: health condition, therapy, why this topic should be prioritised. 
 
Topic 2: health condition, therapy, why this topic should be prioritised. 
 
Topic 3: health condition, therapy, why this topic should be prioritised. 
 
Topic 4: health condition, therapy, why this topic should be prioritised. 
 
Topic 5: health condition, therapy, why this topic should be prioritised. 
 
Topic 6: health condition, therapy, why this topic should be prioritised. 
 
Topic 7: health condition, therapy, why this topic should be prioritised. 
 
Topic 8: health condition, therapy, why this topic should be prioritised. 
 
Topic 9: health condition, therapy, why this topic should be prioritised. 
 
Topic 10: health condition, therapy, why this topic should be prioritised. 
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APPENDIX B – Systematic review topics prioritised in Round 1 
(Question 4) 
Answer Choices Responses 
N(%) 
Acute respiratory infection: nonspecific - Nonsteroidal anti - inflammatory drugs (NSAIDs) - 
existing evidence: 36 RCTs 
50 (38) 
Influenza - Infection control – existing evidence: 5 RCTs 50 (38) 
Acute respiratory infection: nonspecific - Vitamin C - existing evidence: 11 RCTs 49 (37) 
Acute respiratory infection: nonspecific - Corticosteroid - existing evidence: 8 RCTs 48 (36) 
Common cold - Vitamins and supplements - existing evidence: 5 RCTs 45 (34) 
Acute respiratory infection: nonspecific - Vitamins and supplements - existing evidence: 19 
RCTs 
42 (32) 
Influenza - Vaccination reminder – existing evidence: 17 RCTs 40 (30) 
Bronchiolitis - Complementary and alternative medicine (CAM) - existing evidence: 17 RCTs 38 (29) 
Streptococcus / "strep"  - Vaccination - existing evidence: 5 RCTs 38 (29) 
Common cold - Antiviral - existing evidence: 27 RCTs 36 (27) 
Influenza - Diagnostic test – existing evidence: 5 RCTs 36 (27) 
Pharyngitis / sore throat - Nonsteroidal anti - inflammatory drugs (NSAIDs) - existing evidence: 
31 RCTs 
36 (27) 
Sinusitis - Complementary and alternative medicine (CAM) - existing evidence: 10 RCTs 36 (27) 
Acute respiratory infection: nonspecific - Vaccination - existing evidence: 18 RCTs 35 (26) 
Common cold - Nasal lavage - existing evidence: 5 RCTs 35 (26) 
Acute respiratory infection: nonspecific - Antiviral - existing evidence: 10 RCTs 34 (26) 
Influenza - Vitamins and supplements – existing evidence: 5 RCTs 34 (26) 
Acute respiratory infection: nonspecific - Paracetamol - existing evidence: 9 RCTs 33 (25) 
Influenza - Nonsteroidal anti - inflammatory drugs (NSAIDs) – existing evidence: 5 RCTs 33 (25) 
Vaccination adverse effects - Anaesthetic - existing evidence: 5 RCTs 33 (25) 
Bronchiolitis - Saline – existing evidence: 12 RCTs 32 (24) 
Pneumonia - Delivery of health care - existing evidence: 12 RCTs 32 (24) 
Pneumonia - Humidification / steam - existing evidence: 16 RCTs 30 (23) 
Pneumonia - Antiviral - existing evidence: 5 RCTs 29 (22) 
Otitis media - Antitussive  / decongestant / expectorant / mucolytic – existing evidence: 23 
RCTs 
28 (21) 
Acute respiratory infection: nonspecific - Zinc - existing evidence: 9 RCTs 27 (20) 
Bronchiolitis - Antitussive  / decongestant / expectorant / mucolytic – existing evidence: 6 RCTs 27 (20) 
Pneumonia - Complementary and alternative medicine (CAM) - existing evidence: 9 RCTs 27 (20) 
Bronchiolitis - Vaccination – existing evidence: 6 RCTs 26 (20) 
Common cold - Immunotherapy - existing evidence: 34 RCTs 26 (20) 
Bronchiolitis - Antiviral - existing evidence: 5 RCTs 25 (19) 
Otitis media - Antihistamine – existing evidence: 13 RCTs 25 (19) 
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Answer Choices Responses 
N(%) 
Common cold - Analgesic / antipyretic - existing evidence: 7 RCTs 24 (18) 
Otitis media - Complementary and alternative medicine (CAM) – existing evidence: 10 RCTs 24 (18) 
Otitis media - Corticosteroid – existing evidence: 9 RCTs 24 (18) 
Respiratory syncytial virus - Vaccination - existing evidence: 15 RCTs 24 (18) 
Respiratory syncytial virus - Corticosteroid - existing evidence: 12 RCTs 24 (18) 
Acute respiratory infection: nonspecific - Analgesic / antipyretic - existing evidence: 7 RCTs 23 (17) 
Pneumonia - Ventilation - existing evidence: 7 RCTs 23 (17) 
Respiratory syncytial virus - Antiviral - existing evidence: 16 RCTs 23 (17) 
Pharyngitis / sore throat - Paracetamol - existing evidence: 6 RCTs 22 (17) 
Pharyngitis / sore throat - Analgesic / antipyretic - existing evidence: 5 RCTs 22 (17) 
Infectious mononucleosis - Antiviral - existing evidence: 10 RCTs 21 (16) 
Influenza - Immunotherapy – existing evidence: 13 RCTs 21 (16) 
Adenovirus - Vaccination - existing evidence: 6 Randomised Controlled Trials (RCTs) 20 (15) 
Meningitis - Antifungal – existing evidence: 7 RCTs 20 (15) 
Otitis media - Delivery of health care – existing evidence: 6 RCTs 20 (15) 
Respiratory syncytial virus - Immunotherapy - existing evidence: 5 RCTs 20 (15) 
Acute respiratory infection: nonspecific - Vitamin A - existing evidence: 23 RCTs 19 (14) 
Pharyngitis / sore throat - Antiseptic - existing evidence: 7 RCTs 19 (14) 
Otitis media - Nonsteroidal anti - inflammatory drugs (NSAIDs) – existing evidence: 7 RCTs 18 (14) 
Acute respiratory infection: nonspecific - Immunoglobulin - existing evidence: 7 RCTs 17 (13) 
Pharyngitis / sore throat - Vaccination - existing evidence: 5 RCTs 17 (13) 
Acute respiratory infection: nonspecific - Antiseptic - existing evidence: 5 RCTs 16 (12) 
Bronchitis, acute - Zinc - existing evidence: 7 RCTs 16 (12) 
Pneumonia - Oral care - existing evidence: 7 RCTs 16 (12) 
Bronchiolitis - Immunotherapy - existing evidence: 5 RCTs 13 (10) 
Otitis media - Surgery – existing evidence: 5 RCTs 12 (9) 
Pneumonia - H2 Antagonist (i.e. H2 blockers) - existing evidence: 9 RCTs 11 (8) 
Pneumonia - Immunoglobulin - existing evidence: 7 RCTs 11 (8) 
Pneumonia - Antiseptic - existing evidence: 8 RCTs 10 (8) 
Acute respiratory infection: nonspecific - Mast cell stabiliser - existing evidence: 5 RCTs 9 (7) 
Common cold - Flavinoid - existing evidence: 5 RCTs 9 (7) 
Pneumonia - Granulocyte - colony stimulating factor (G - CSF) - existing evidence: 6 RCTs 9 (7) 
Pneumonia - Sucralfate - existing evidence: 5 RCTs 8 (6) 
Pharyngitis / sore throat - Immunotherapy - existing evidence: 5 RCTs 7 (5) 
Pneumonia - Enteral nutrition - existing evidence: 6 RCTs 7 (5) 
Pneumonia - Suction - existing evidence: 11 RCTs 6 (5) 
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Appendix C – Additional priority systematic review topics suggested in Round 1  
 
Health condition Intervention  Additional information (if 
provided) 
Existing Cochrane 
review? 
Cochrane Systematic Review Title 
Airway oedema Epinephrine  For minimising No N/A 
ARI Inhaled corticosteroids -- Yes Corticosteroids for the common cold 
ARI Acupuncture -- No N/A 
ARI Honey -- Yes Honey for acute cough in children 
ARI Vitamin D In children under 5 Yes Vitamin D supplementation for preventing infections in children 
under five years of age – covers pneumonia 
ARI Physical interventions for 
reducing 
An update Yes Exercise versus no exercise for the occurrence, severity and 
duration of acute respiratory infections 
ARI Samahan (Ayurvedic 
medicine) 
-- No N/A 
Asthma Immunostimulants  In children, for reduction of 
ARIs 
Yes Immunostimulants for preventing respiratory tract infection in 
children – last updated 2006 
Asthma (acute) Corticosteroids -- Yes Early use of inhaled corticosteroids in the emergency department 
treatment of acute asthma 
Asthma (acute) Immunotherapy -- No No 
Bronchiolitis Oxygen -- Yes Heliox inhalation therapy for bronchiolitis in infants 
Bronchiolitis Supportive care  In children No No 
Bronchiolitis Beta-agonists -- Yes Anticholinergic drugs for wheeze in children under the age of two 
years 
Bronchitis (acute) NSAIDs  As alternative to antibiotics Yes Non-steroidal anti-inflammatory drugs for the common cold 
Bronchitis (acute) Chest physiotherapy -- Yes Chest physiotherapy for pneumonia in adults and children 
Bronchospasm Inhaled corticosteroids.  Population: neonatal No No 
Common cold Honey -- Yes Honey and lozenges for children with non-specific cough 
Common cold Echinacea  As a prophylactic Yes Echinacea for preventing and treating the common cold 
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Health condition Intervention  Additional information (if 
provided) 
Existing Cochrane 
review? 
Cochrane Systematic Review Title 
Common cold Green tea -- No No 
Common cold Herbal medicines -- Yes Chinese medicinal herbs for the common cold 
Common cold Honey -- Yes Honey and lozenges for children with non-specific cough 
Common cold Nasal irrigation  As a prophylactic Yes Saline nasal irrigation for acute upper respiratory tract infections 
Common cold Honey and tulsi -- No N/A 
Common cold Lemon  What form is most 
effective (lemon juice, 
lemon bits, etc.) 
No N/A 
Common cold Vitamin c  As a prophylactic Yes Vitamin C for preventing and treating the common cold 
Common cold Zinc  Timing – to either prevent 
or shorten duration 
Yes Zinc for preventing and treating the common cold 
COPD Long-acting bronchodilators -- Yes Bronchodilators delivered by nebuliser versus pMDI with spacer or 
DPI for exacerbations of COPD 
Cough Inhaled corticosteroids.  Population: children Yes Inhaled corticosteroids for subacute cough in children 
Cough Inhaled bronchodilators Population: children Yes Bronchodilators for bronchiolitis 
Dysphagia Prokinetic agents  For preventing 
bronchoaspiration 
No N/A 
Endocarditis Addition of aminoglycoside 
to beta-lactam 
-- Yes A comparison of different antibiotic regimens for the treatment of 
infective endocarditis 
Influenza Masks  As means of reducing 
transmission 
Yes Physical interventions to interrupt or reduce the spread of 
respiratory viruses 
Influenza Vaccine harms -- Yes Vaccines for preventing influenza in healthy adults – contains harms 
information 
Influenza Vaccine harms -- Yes Vaccines for preventing influenza in healthy adults – contains harms 
information 
Influenza Vaccine harms  Does vaccine cause a 
'common cold' type 
reaction 
Yes Vaccines for preventing influenza in healthy adults – contains harms 
information 
Influenza Vaccine  -- Yes Vaccines for preventing influenza in healthy adults 
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Health condition Intervention  Additional information (if 
provided) 
Existing Cochrane 
review? 
Cochrane Systematic Review Title 
Influenza Antiviral  Prophylaxis in aged care 
facilities 
No N/A 
Influenza Ventilatory support -- No N/A 
Influenza Vaccine effectiveness.  Population: patients taking 
methotexate 
No N/A 
Influenza Self-management 
approaches 
-- Yes Saline nasal irrigation for acute upper respiratory tract infections 
Influenza and URI Vitamin C -- No N/A 
Nasal congestion Nasal cleaning with saline 
solution 
-- Yes Nasal saline irrigations for the symptoms of chronic rhinosinusitis 
Nasal congestion Saline nasal spray -- Yes Nasal saline irrigations for the symptoms of chronic rhinosinusitis 
Otitis media Corticosteroids -- Yes Systemic corticosteroids for acute otitis media in children 
Otitis media Nasal cleaning with saline 
solution 
-- No N/A 
Otitis Media 
(Acute) 
Antibiotics  Setting: developing 
countries 
No General reviews exist in this area but none are specific to 
developing countries 
Otitis Media 
(Acute) 
Topical decongestants -- Yes Decongestants and antihistamines for acute otitis media in children 
Otitis Media 
(Acute) 
Antibiotics   Population: children Yes Antibiotics for acute otitis media in children 
Pharyngitis Honey Population: adults Yes Over-the-counter (OTC) medications for acute cough in children and 
adults in community settings 
Pharyngitis Honey -- Yes Honey for acute cough in children 
Pharyngitis (sore 
throat) 
Salt solution  To decrease the infection 
going down in the lungs 
Yes Saline nasal irrigation for acute upper respiratory tract infections 
Pharyngitis (sore 
throat) 
Honey  As a prophylactic Yes Honey for acute cough in children 
Pharyngitis (sore 
throat) 
Honey -- Yes Honey for acute cough in children 
26 
 
Health condition Intervention  Additional information (if 
provided) 
Existing Cochrane 
review? 
Cochrane Systematic Review Title 
Pharyngitis (sore 
throat) and 
tonsillitis 
Antiseptic/analgesic gargles -- Yes Oral rinses, mouthwashes and sprays for improving recovery 
following tonsillectomy 
Pneumonia Molecular diagnostics, 
targeted treatment 
-- No N/A 
Pneumonia Home based newborn care 
programme 
For minimising pneumonia No N/A 
Pneumonia Diet  Role in recovery No N/A 
Pneumonia Walking in fresh air  Role in recovery) No N/A 
Pneumonia Humidification  As adjuvant therapy No N/A 
Pneumonia Antibiotic harms  E.g. cardiotoxicity of 
macrolides 
Yes Protocol - Adverse events in patients taking macrolide antibiotics 
versus placebo for any indication 
Pneumonia RSV antiviral treatment.  Population: adults Yes Monoclonal antibody for reducing the risk of respiratory syncytial 
virus infection in children 
Pneumonia Steroids -- Yes Corticosteroids for pneumonia 
Pneumonia Poststenotic treatment -- No N/A 
Pneumonia Duration of antibiotic 
therapy 
-- Yes Short-course versus prolonged-course antibiotic therapy for 
hospital-acquired pneumonia in critically ill adults 
Pneumonia Postestenotic treatment -- No N/A 
Pneumonia (CAP) Anti-influenza antivirals or 
not 
-- Yes Amantadine and rimantadine for influenza A in children and the 
elderly 
Pneumonia (CAP, 
HAP and VAP) 
Duration of antibiotic 
therapy 
-- Yes Short-course versus prolonged-course antibiotic therapy for 
hospital-acquired pneumonia in critically ill adults 
Pneumonia 
(severe, 
community 
acquired) 
Macrolides vs quinolones -- Yes Empiric antibiotic coverage of atypical pathogens for community-
acquired pneumonia in hospitalized adults 
Respiratory 
distress 
syndrome (acute) 
ECMO -- Yes Extracorporeal membrane oxygenation for critically ill adults 
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Health condition Intervention  Additional information (if 
provided) 
Existing Cochrane 
review? 
Cochrane Systematic Review Title 
Respiratory 
illness 
Echinacea  As a prophylactic Yes Echinacea for preventing and treating the common cold 
Respiratory virus 
transmission 
Copper  For reducing of 
transmission 
No N/A 
Rhinosinusitis Criteria for clinical diagnosis  -- No N/A 
Rhinosinusitis 
(acute) 
Herbal medicine -- Yes Chinese medicinal herbs for the common cold, nothing rhinosinusitis 
specific 
Sinusitis Netipot  -- Yes Saline irrigation for chronic rhinosinusitis 
Sinusitis Oxymetazoline -- Yes Nasal decongestants in monotherapy for the common cold 
Sinusitis Inhaled nasal 
corticosteroids 
-- Yes corticosteroids for acute sinusitis 
Sinusitis Essential oils -- No N/A 
Sinusitis (acute) Nasal corticosteroids -- Yes Systemic corticosteroids for acute sinusitis 
Sinusitis (acute) Saline irrigation -- Yes Saline irrigation for chronic rhinosinusitis 
Sore throat Rapid tests  To reduce AB prescription 
in these patients 
Yes Rapid antigen detection test for group A streptococcus in children 
with pharyngitis 
Sore throat Molecular rapid tests 
(diagnostics) 
-- Yes Rapid antigen detection test for group A streptococcus in children 
with pharyngitis 
URI homeopathy    -- Yes Homeopathic Oscillococcinum® for preventing and treating 
influenza and influenza-like illness 
URI UV light  For reduction of URI in 
triage areas 
No N/A 
URTI Antibiotics  Setting: developing 
countries 
No Reviews exist on this topic but none are specific to developing 
countries 
URTI or common 
cold 
Saline nasal drop or nasal 
irrigation.  
Population: infants and 
young children 
Yes Nasal saline irrigations for the symptoms of chronic rhinosinusitis 
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APPENDIX D – Systematic review topics prioritised in Round 2 
 
Answer Choices Responses 
N(%) 
Acute respiratory infection: nonspecific - Antiviral - existing evidence: 10 RCTs 36 (46) 
Acute respiratory infection: nonspecific - Corticosteroid - existing evidence: 8 RCTs 28 (36) 
Acute respiratory infection: nonspecific - Nonsteroidal anti-inflammatory drugs (NSAIDs) - 
existing evidence: 36 RCTs 
34 (44) 
Acute respiratory infection: nonspecific - Paracetamol - existing evidence: 9 RCTs 17 (22) 
Acute respiratory infection: nonspecific - Vaccination - existing evidence: 18 RCTs 40 (51) 
Acute respiratory infection: nonspecific - Vitamin C - existing evidence: 11 RCTs 26 (33) 
Acute respiratory infection: nonspecific - Vitamins and supplements - existing evidence: 19 
RCTs 
34 (44) 
Bronchiolitis - Complementary and alternative medicine (CAM) - existing evidence: 17 RCTs 27 (35) 
Bronchiolitis - Saline – existing evidence: 12 RCTs 21 (27) 
Common cold - Antiviral - existing evidence: 27 RCTs 25 (32) 
Common cold - Nasal lavage - existing evidence: 5 RCTs 23 (29) 
Common cold - Vitamins and supplements - existing evidence: 5 RCTs 18 (23) 
Influenza - Diagnostic test – existing evidence: 5 RCTs 26 (33) 
Influenza - Infection control – existing evidence: 5 RCTs 32 (41) 
Influenza - Nonsteroidal anti-inflammatory drugs (NSAIDs) – existing evidence: 5 RCTs 14 (18) 
Influenza - Vaccination reminder – existing evidence: 17 RCTs 21 (27) 
Influenza - Vitamins and supplements – existing evidence: 5 RCTs 19 (24) 
Otitis media - Antitussive / decongestant / expectorant / mucolytic – existing evidence: 23 
RCTs 
32 (41) 
Pharyngitis / sore throat - Nonsteroidal anti-inflammatory drugs (NSAIDs) - existing evidence: 
31 RCTs 
32 (41) 
Pneumonia - Antiviral - existing evidence: 5 RCTs 25 (32) 
Pneumonia - Delivery of healthcare - existing evidence: 12 RCTs 26 (33) 
Pneumonia - Humidification/steam - existing evidence: 16 RCTs 23 (29) 
Sinusitis - Complementary and alternative medicine (CAM) - existing evidence: 10 RCTs 30 (38) 
Streptococcus / "strep" - Vaccination - existing evidence: 5 RCTs 22 (28) 
Vaccination adverse effects - Anaesthetic - existing evidence: 5 RCTs 23 (29) 
 
 
 
